Press Release

Vigilant Biosciences Announces OncAlert™ Oral Cancer Product Line Now Shipping December 20, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that its OncAlert™ Oral Cancer product line is now shipping and available in select countries. Additionally, the Company announced

Vigilant Biosciences Announces New Distribution Partnership Agreements for OncAlert™ Oral Cancer Product Line for Spain, Portugal and Germany November 14, 2016 FORT LAUDERDALE, Florida and DUSSELDORF, Germany Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced exclusive multi-year distribution agreement for

Vigilant Biosciences Announces Oral Presentation on Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer at the American Academy of Otolaryngology–Head and Neck Surgery Foundation 2016 Annual Meeting September 16, 2016 FORT LAUDERDALE, Florida and SAN DIEGO Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and

Vigilant Biosciences Announces Poster Presentation on Measuring CD44 and Total Protein Levels to Predict Head and Neck Squamous Cell Carcinoma at 7th European Conference on Head and Neck Oncology September 6, 2016 FORT LAUDERDALE, Florida and BUDAPEST, Hungary Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and

Vigilant Biosciences Awarded Phase I SBIR Grant for Next Generation Oral Cancer Diagnostic System August 11, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant

Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer July 13, 2016 FORT LAUDERDALE, Florida and SEATTLE Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention

Vigilant Biosciences Raises $5 Million Second Round Series B Financing July 11, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the successful completion of a $5 million round of financing through its Series B2 offering, bringing

Vigilant Biosciences Announces Three New Distribution Agreements for OncAlert™ Oral Cancer Product Line for Europe, Africa and Latin America June 15, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced three exclusive multi-year distribution agreements for sales

Vigilant Biosciences Announces the Launch of the OncAlert Labs OraMark™ Test to Aid U.S. Clinicians in the Early Detection of Oral Cancer May 31, 2016 FORT LAUDERDALE, Florida and CHICAGO Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the launch

Vigilant Biosciences, Inc. Names Scientific Advisory Board and Expands Leadership Team, Appoints Dr. Michael Donovan as Chief Clinical Officer May 25, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the launch of a Scientific Advisory Board